Clinical Trials Logo

Clinical Trial Summary

B7-H3 (also known as CD276) is widely expressed on the surface of a variety of malignancies solid tumors, while it rarely or even doesn't express on normal tissues. Therefore, B7-H3 is an ideal target for chimeric antigen receptor (CAR) T cells therapy. TAA06 injection is a CAR T injection targeting B7-H3. This is a phase I clinical study with the primary objective of evaluating the safety and tolerability of TAA06 injection in subjects with TAA06-positive advanced solid tumors. The secondary objectives are as follows: to evaluate the distribution, proliferation and persistence of B7-H3-targeted CAR T cells after injection of TAA06 in subjects; to preliminarily evaluate the efficacy of TAA06 injection in subjects with TAA06-positive advanced solid tumor.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05190185
Study type Interventional
Source PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Contact Zhiyu Wang, Doctor
Phone +86-138 3119 5070
Email [email protected]
Status Recruiting
Phase Phase 1
Start date June 1, 2021
Completion date December 1, 2023